A Double-blind Placebo-controlled, Randomised, Single Centre, First Time in Man Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Inhaled Doses of AZD7624 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 08 Apr 2015
At a glance
- Drugs AZD 7624 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions
- 06 Sep 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 22 Aug 2013 Planned number of patients changed from 56 to 72 as reported by ClinicalTrials.gov.
- 22 Aug 2013 Planned End Date changed from 1 May 2013 to 1 Oct 2013 as reported by ClinicalTrials.gov.